Search results
Author(s):
Marianna Fontana
Added:
5 months ago
AHA Conference 2024 - Safety and efficacy outcomes of nexiguran ziclumeran (NTLA-2001) in patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM).Dr Marianna Fontana (University College London, London, UK) joins us onsite at AHA Conference to discuss the findings from the nexiguran ziclumeran for ATTR-CM trial (NCT04601051).Dr Fontana discusses a phase 1, ongoing, open-label, single…
View more
Author(s):
Marianna Fontana
Added:
1 year ago
Prof Marianna Fontana (University College London, UK) joined us to discuss the discovery and impact of antibody-associated reversal of ATTR amyloidosis–related cardiomyopathy in three patients.
Prof Fontana and her team, in a correspondence published in The New England Journal of Medicine, revealed the identification of an antibody linked to the spontaneous reversal of cardiac transthyretin…
View more
Author(s):
Julian Gillmore
Added:
1 year ago
ESC 2023 — Prof Julian Gillmore (University College London, UK) joins us onsite to discuss the findings of the ATTRibute-CM Study (NCT03860935).
ATTRibute-CM was a randomised double-blind trial which aimed to evaluate the safety and efficacy of acoramidis in a cohort of patients diagnosed with transtherytin amyloid cardiomyopathy (ATTR-CM). 632 patients were enrolled in the trial, and were…
View more
Author(s):
Demilade Adedinsewo
Added:
1 year ago
AHA 23 - We are joined by Dr Demilade Adedinsewo (Mayo Clinic, US) to discuss the findings from a study investigating the effectiveness of an artificial intelligence-enabled ECG (AI-ECG) for cardiomyopathy detection in an obstetric population.In the intervention arm, the digital stethoscope correctly identified 92% of those with ejection fraction <50% and 100% of those with ejection fraction …
View more
Author(s):
Elena Arbelo
,
Juan-Pablo Kaski
Start date:
Aug 27, 2023
Live from ESC 2023 in Amsterdam, this broadcast will bring together the chairpersons of the latest ESC Guidelines on Cardiomyopathy, released on Sunday 27 August 2023.
Prof Elena Arbelo (Hospital Clinic, Barcelona, ES) andProf Juan Pablo Kaski (University College London, UK) will provide definitive commentary on the guideline updates – including what's new in hypertrophic cardiomyopathy (HCM),…
View more
Author(s):
Milind Y Desai
Added:
1 month ago
ACC 2025 - First-in-human results from MyPEAK-1 show Tn-201 treatment in adults with Mybpc3-associated hypertropic cardiomyopathy was feasible and safe.Dr Milind Desai (Cleveland Clinic, Ohio, US) joins us onsite at ACC 2025 to discuss phase Ib/2a results from the first-in-human, non-randomized study investigating the safety and early efficacy of Tn-201, an adeno-associated virus serotype 9 gene…
View more
Author(s):
Ahmad Masri
Added:
1 year ago
ESC-HFA 23 — We are joined by Dr Ahmad Masri (Oregon Health & Science University Medical Group, US) to discuss the findings from REDWOOD-HCM cohort 4 (NCT04219826).
This study assessed the safety and tolerability of the selective inhibitor of cardiac myosin, aficamten (Cytokinetics) in patients with symptomatic nHCM. Cohort 4 included 41 patients. The data presented at HFA 23 shows that…
View more
Konstantinos C Siontis
Job title: Cardiac Electrophysiologist, Assistant Professor of Medicine
Author
Juan-Pablo Kaski
Research Area(s) / Expertise:
Job title: Associate Professor
Author
Silvia Castelletti
Research Area(s) / Expertise:
Author